Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verastem Inc (NQ: VSTM )

4.570 +0.520 (+12.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verastem Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 200 companies hit new 52-week lows. 
Via Benzinga
RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm
Via Benzinga
Verastem Oncology Appoints Rob Gagnon to Board of Directors
From Verastem Oncology
Via Business Wire
Cigna To Rally 15%? Plus Needham Slashes PT On This Stock By 40%
Raymond James raised the price target on Cigna Corporation (NYSE: CI) from $330 to $370. Raymond James analyst John Ransom maintained a Strong Buy rating on the stock. Cigna shares rose 0.1% to $322.17... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Cidara Therapeutics (NASDAQ:CDTX) shares rose 14.6% to $0.64 during Monday's pre-market session. The market value of their outstanding shares is at $44.9 million. The company's, Q3 earnings... 
Via Benzinga
Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
10 Best Medical Stocks Under $5
The medical industry is one of the most lucrative sectors globally, and it is one that sees the highest spending in terms of research and development, and breakthrough advances through keeping up the... 
Via Talk Markets
Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday
Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company. 
Via Benzinga
Verastem Oncology Appoints Anil Kapur to Board of Directors
From Verastem Oncology
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
  During Monday's trading, 528 companies set new 52-week lows. 
Via Benzinga
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Why KalVista Pharmaceuticals Shares Are Trading Lower By 59%; Here Are 89 Biggest Movers From Yesterday
   Losers 
Via Benzinga
S&P 500 Rises 100 Points; Nasdaq Up 3%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 127 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 44 companies hit new 52-week lows. 
Via Benzinga
Nasdaq Surges 350 Points; Crude Oil Rises Sharply
U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 350 points on Tuesday. 
Via Benzinga
Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
7 Cheap Biotech Stocks to Buy Now
These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains. 
Via InvestorPlace
Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer
From Verastem Oncology
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.